Drugs / bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03714737 | May 2016 → Sep 2017 | — | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine | “bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)” NCT03714737 ↗ |
| Known as | MenAC-TT | “meningococcal serogroups A and C tetanus toxoid-conjugate vaccine (MenAC-TT)” PMID 31348731 ↗ Jul 2019 |
| Modality | Vaccine | “bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)” NCT03714737 ↗ |